Peginterferon alfa-2a
Regulatory milestones approvals, filings & regulatory actions · 11 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (9) | US (FDA) | PEGASYS | — | 2002-12-03 – 2023-12-11 | fda.gov ↗ |
| Approved | US (FDA) | PEGASYS | — | 2002-10-16 | fda.gov ↗ |
| Approved | EU (EMA) | Pegasys | — | 2002-06-20 | europa.eu ↗ |
Trials 294 · started per year
Also used as a comparator or background therapy in 256 trials
Press releases naming this drug 7 releases
| Date | Issuer | Release |
|---|---|---|
| 2012-04-19 | Gilead Sciences | Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients gilead.com ↗ |
| 2012-04-19 | Bristol-Myers Squibb | Investigational Compound Peginterferon Lambda Achieved SVR24 Rates Comparable to Peginterferon Alfa with Fewer Flu-Like and Musculoskeletal Symptoms in Phase IIb Study in Treatment-Naïve Genotype 2 or 3 Hepatitis C Patients bms.com ↗ |
| 2011-09-04 | Gilead Sciences | Gilead Amends Study Design for Ongoing Hepatitis C Clinical Trials That Include GS 9190, Pegylated Interferon and Ribavirin, and Another Direct-Acting Antiviral Agent gilead.com ↗ |
| 2008-04-24 | Vertex Pharmaceuticals Incorporated | Vertex Announces Positive Interim Results with Telaprevir-based Therapy in Genotype 1 Chronic Hepatitis C Patients who Failed to Achieve SVR with Previous Pegylated Interferon & Ribavirin Treatment vrtx.com ↗ |
| 2006-05-21 | Vertex Pharmaceuticals Incorporated | Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients vrtx.com ↗ |
| 2006-04-29 | Vertex Pharmaceuticals Incorporated | Researchers Report Initial Results for 14-day Phase Ib Study of VX-950, and Pegylated Interferon, Showing Anti-HCV Activity in Combination in Hepatitis C Patients vrtx.com ↗ |
| 2006-01-09 | Vertex Pharmaceuticals Incorporated | VX-950, Investigational Oral Hepatitis C Protease Inhibitor, Demonstrates Rapid and Dramatic Reduction in Viral Levels in Combination with Pegylated Interferon vrtx.com ↗ |
Evidence & citations 67 cited values
Every value below carries the sentence it was read from. 595 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Peginterferon Alfa-2a | “A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group...” NCT00535847 ↗246“A Pilot, Open-Label, Multicentre Study Evaluating the Long-Term Safety and Tolerability of a Low-Dose Peginterferon Alfa-2a Maintenance Monotherapy in Chronic Hepatitis C...” NCT02762383 ↗ “Recently the investigators have shown that HBeAg negative patients with high HBV-DNA load and low baseline HBsAg levels had a significantly higher HBsAg clearance (positive...” NCT00973219 ↗ “The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than...” NCT00008463 ↗ “The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of...” NCT00100659 ↗ “Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8...” NCT01368497 ↗ “An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide...” NCT02068365 ↗ “Pegasys (peginterferon alfa-2a) given in combination with Copegus (ribavirin) given for 24 weeks or 48 weeks in treatment naïve patients with chronic hepatitis C (CHC).” NCT00188240 ↗ “HBeAg-negative patients received peginterferon alfa-2a (180 μg/week) ± lamivudine (100 mg/day) for 48 weeks as part of a multicenter, randomized study.” PMID 23518903 ↗ Mar 2012 “patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks” NCT01471535 ↗ “We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.” PMID 28210927 ↗ Feb 2017 “we gave patients peginterferon alfa-2a 45 μg per week combined with nilotinib 600 mg daily until 24 months after interferon initiation.” PMID 26687426 ↗ Jan 2015 “peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial.” PMID 30833068 ↗ Mar 2019 “Adult HBeAg+ interferon-naive patients were randomized (1:1) to weekly lambda (180 μg) or peginterferon alfa-2a (alfa) for 48 weeks.” PMID 26739688 ↗ Dec 2015 “faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection.” PMID 27049487 ↗ May 2016 “Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day” NCT00532701 ↗ “All patients will receive the standard recommended doses of peginterferon alfa 2a (180 mcg sc weekly) and ribavirin” NCT00718172 ↗ “Peginterferon Alfa-2A 180 micrograms/week or Peginterferon Alfa-2B 180 micrograms/week, for at most 96 weeks.” NCT03801538 ↗ “peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.” NCT02893124 ↗ “peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.” NCT02908763 ↗ “Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.” NCT00996216 ↗ “Peginterferon alfa-2a 180 Mcg infusion per week with ongoing NUCLEOTIDE ANALOGUES for 48 weeks.” NCT02982837 ↗ “standard dose Peg-Interferon alfa-2a (PEG-IFN alfa-2a), Ribavirin (RBV) and Amantadine (AMA)” NCT00299923 ↗ “peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week” NCT02745704 ↗ “Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01808248 ↗ “Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly” NCT01260350 ↗ “Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.” NCT01706575 ↗ “asunaprevir, daclatasvir, peginterferon alfa-2a and ribavirin for 24 weeks” NCT01888900 ↗ “Subcutaneous injection of Peginterferon Alfa-2a 180 μg once per week.” NCT03957629 ↗ “the combination therapy (peginterferon alfa-2a and ribavirin)” NCT00485342 ↗ “Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug” NCT00977054 ↗ “Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52” NCT00917761 ↗ “Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®)” NCT00420784 ↗ “peginterferon alfa-2a (solution for injection) 180 µg/week” NCT01271790 ↗ “peginterferon alfa-2a at 180ug/week (preempt syringe, sc)” NCT01195181 ↗ “peginterferon alfa 2 a 180 mcg/week plus RBV 1600 mg/day” NCT00830609 ↗ “Peg-interferon alfa-2a was continued for up to 12 weeks” PMID 23105144 ↗ Oct 2012 “peginterferon alfa-2a (PegIFNα-2a) and ribavirin (RBV)” NCT00882908 ↗ “Pegasys (peginterferon alfa-2a) pharmacokinetics” NCT01337375 ↗ “Pegasys (peginterferon alfa-2a) pharmacokinetics” NCT01337375 ↗ “peginterferon alfa-2a (PEGASYS, PEG-IFNalfa-2a)” NCT00115908 ↗ “Peg-interferon alfa 2a: 180 mcg 1x per wk.” NCT00759200 ↗ “PEGASYS® (peginterferon alfa-2a, PegIFN)” NCT01937728 ↗ “peginterferon alfa-2a 180mcg x 24 weeks” NCT03575208 ↗ “Peginterferon alfa-2a 180ug per week” NCT03771677 ↗ “Peginterferon alfa-2a and ribavirin” NCT00491244 ↗ “Peginterferon Alfa-2a (Pegasys®)” NCT00372385 ↗ “Biological: PEGinterferon alfa2a” NCT01178996 ↗ “Pegasys (peginterferon alfa-2a)” NCT01220947 ↗ “Peginterferon Alfa-2a (Pegasys)” NCT01265511 ↗ “PEGASYS [peginterferon alfa-2a]” NCT00442572 ↗ “peginterferon alfa-2a (pegasys)” NCT01378104 ↗ “PEGASYS (peginterferon alfa-2a)” NCT00081770 ↗ “peginterferon alfa-2a [Pegasys]” NCT01033448 ↗ “• PEG interferon alfa-2a” NCT07623200 ↗ “Peginterferon alfa-2a” NCT00892697 ↗ |
| Known as | 40 Kd Pegylated interferon alfa 2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02087111 ↗ |
| Known as | alfa | “Adult HBeAg+ interferon-naive patients were randomized (1:1) to weekly lambda (180 μg) or peginterferon alfa-2a (alfa) for 48 weeks.” PMID 26739688 ↗ Dec 2015 |
| Known as | Best Available Treatment | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07623200 ↗ |
| Known as | interferon alfa 2 a | “interferon alfa 2 a (pegylated form improving tolerance and maybe enhancing is efficacy)” NCT02201459 ↗ |
| Known as | Interferon alpha-2a recombinant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02763969 ↗ |
| Known as | Interféron pégylé alpha -2a | “PEGASYS 180μg (Interféron pégylé alpha -2a)” NCT00391638 ↗ |
| Known as | P-IFN alfa 2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02112630 ↗ |
| Known as | PEG | “This study is to evaluate the overall efficacy, and safety profile of the triple combination therapy of alisporivir (ALV; DEB025) plus peginterferon alfa-2a (PEG) and ribavirin...” NCT01500772 ↗15“This study will assess the safety and efficacy of alisporivir (ALV) and boceprevir (BOC), each in combination with Peginterferon alfa-2a (PEG) and Ribavirin (RBV), in African...” NCT01446250 ↗ “triple therapy with Pegylated interferon alfa(PEG)/Ribavirin(RBV)/Boceprevir(BOC) treatment before liver transplantation(LT)” NCT02160080 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.” NCT01188772 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.” NCT01054729 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection” NCT02480686 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01329978 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01384383 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT02583685 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01641640 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01497366 ↗ “Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01565889 ↗ “Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01808248 ↗ “Pegylated-interferon alfa-2a (PEG) will be delivered subcutaneously once weekly.” NCT02541409 ↗ “Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly” NCT01260350 ↗ “Pegylated interferon alfa-2a (PEG)” NCT00991289 ↗ |
| Known as | PEG Intron | “Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily...” NCT01838772 ↗2“A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma” NCT00027742 ↗ “Recently, a new preparation of interferon namely pegylated interferon (PEG Intron) has become available.” NCT00323505 ↗ |
| Known as | PEG-2a | “The purpose of this study is to determine the safety and efficacy of peginterferon alfa-2a (PEG-2a) in combination with ribavirin (RV) and PEG-2a alone for the treatment of...” NCT00100659 ↗ |
| Known as | PEG-IFN | “Recently the investigators have shown that HBeAg negative patients with high HBV-DNA load and low baseline HBsAg levels had a significantly higher HBsAg clearance (positive...” NCT00973219 ↗46“METHODS: A randomized (1:1) trial of tenofovir disoproxil fumarate (TDF) for 192 weeks with or without peginterferon (PegIFN) alfa-2a for the first 24 weeks, followed by...” PMID 36599136 ↗ Dec 2022 “The purpose of this study is to see if treatment with PEG-interferon-alfa-2a (PEG-IFN) plus ribavirin is a more effective treatment for hepatitis C virus (HCV) than...” NCT00008463 ↗ “In hepatitis C virus (HCV)-infected patients receiving pegylated interferon (PEG-IFN)/ribavirin (RBV) combination therapy, anemia is a well-known side effect.” PMID 15667486 ↗ Feb 2005 “Currently, combination therapy with peginterferon (Peg-IFN) and ribavirin (RBV) has become the standard of care for chronic hepatitis C (CHC) patients” NCT00977054 ↗ “We evaluated the safety and efficacy of DCV plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in HIV-1/HCV genotype-1-coinfected patients.” PMID 28210927 ↗ Feb 2017 “faldaprevir plus peginterferon alfa-2a/ribavirin (PegIFN/RBV) in treatment-naïve patients with chronic HCV genotype-1 infection.” PMID 27049487 ↗ May 2016 “Coinfected and monoinfected patients were enrolled in a treatment trial for pegylated-interferon alpha-2a (peg-IFN) + ribavirin.” PMID 17058240 ↗ Nov 2006 “pegylated interferon (PegIFN) in patients who had previously failed a standard course of PegIFN/ribavirin (RBV) therapy.” PMID 26733671 ↗ Jan 2016 “patients are randomized to receive peginterferon (pegIFN) alfa-2a 180 microg/week plus either weight-based RBV” PMID 20377423 ↗ Apr 2010 “Subjects will be treated for 24 weeks with PEG-IFN (HIV coinfected subjects will received RBV)” NCT00192569 ↗ “Ribavirin improves treatment response to pegylated-interferon (PEG-IFN) in chronic hepatitis C” PMID 23396509 ↗ Feb 2013 “standard or pegylated interferon alfa \[PEG-IFN\] in combination with ribavirin \[RBV\]” NCT00315432 ↗ “pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly” NCT01826981 ↗ “BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)” NCT00983060 ↗ “pegylated interferon alfa (Peg IFN)(180ug subcutaneous once weekly)” NCT01582035 ↗ “PegIFN is to be injected once per week for 24 or 48 weeks.” NCT01582035 ↗ “nilotinib + pegylated interferon alpha 2a (PEG-IFN).” NCT01294618 ↗ “addition of peg-interferon (Peg-IFN) to imatinib” NCT00297570 ↗ “Comparator: Pegylated-Interferon (Peg-IFN)” NCT00704184 ↗ “PEGASYS® (peginterferon alfa-2a, PegIFN)” NCT01937728 ↗ “pegylated IFN (Peg-IFN)-α-2a 180 μg qwk” PMID 22863266 ↗ Mar 2012 “Pegylated Interferon alpha 2-a (PegIFN)” NCT01854697 ↗ “pegylated interferon alpha2a (peg-IFN)” NCT04365933 ↗ “pegylated interferon alfa-2a (PEG-IFN)” NCT00078403 ↗ “pegylated-interferon alfa-2a (PEG-IFN)” NCT00003542 ↗ “pegylated interferon alpha-2a (pegIFN)” NCT01609933 ↗ “pegylated interferon (PegIFN) alfa-2a” NCT00947349 ↗ “Pegylated-interferon alfa 2a (PegIFN)” NCT01581203 ↗ “pegylated interferon (PegIFN) alfa-2a” PMID 27238752 ↗ May 2016 “Pegylated interferon (PEG-IFN)” NCT01355289 ↗ “Pegylated Interferon (Peg-IFN)” NCT00704405 ↗ “Pegylated interferon (pegIFN)” NCT01314261 ↗ |
| Known as | PEG-IFN alfa | “systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity” NCT00610389 ↗1“Peginterferon Alfa-2a (PEG-IFN alfa)” NCT03852433 ↗ |
| Known as | peg-IFN alfa 2a | “Merimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has shown antiviral activity in nonresponders with chronic hepatitis C (CHC)...” PMID 19852040 ↗ Dec 200934“Patients with hepatitis B e antigen (HBeAg)-positive CHB who received any NA for at least 72 weeks and had a low level of HBV DNA (≤100 IU/mL) were randomized (1:1) to receive...” PMID 35867702 ↗ Jul 2022 “The combination therapy using pegylated interferons (IFNs) such as PEG-IFN alfa-2a has been shown to have a superior efficacy than that using conventional IFN in the treatment...” NCT00154869 ↗ “Treatment with pegylated interferon (peg-IFN) alfa-2a (40KD) results in hepatitis B "e" antigen (HBeAg) seroconversion 6 months after treatment in up to 36% of HBeAg-positive...” PMID 25190434 ↗ Sep 2014 “open-label subcutaneous treatment with pegylated interferon-alfa-2a (Peg-IFNalfa-2a) 180 μg/wk, or albIFN 900 or 1200 μg every 2 weeks for 24 weeks” PMID 20600017 ↗ Jul 2010 “The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.” NCT01513941 ↗ “Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks” NCT00880763 ↗ “One discontinue the NUC treatment ,receive Peg-IFN alfa-2a 180 μg by week for 24 weeks and follow up for 72 weeks” NCT02594293 ↗ “Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment” NCT00078442 ↗ “standard dose Peg-Interferon alfa-2a (PEG-IFN alfa-2a), Ribavirin (RBV) and Amantadine (AMA)” NCT00299923 ↗ “Participants with HCV received pegylated interferon (PEG-IFN) alfa-2a (180μg/week, n=74)” PMID 21145855 ↗ Nov 2010 “Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.” NCT00528528 ↗ “peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW” NCT00842205 ↗ “phase III study evaluated peginterferon (PegIFN) alfa-2a treatment” PMID 29689122 ↗ Oct 2018 “180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks.” NCT01925820 ↗ “with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk)” NCT00892697 ↗ “peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]” NCT00077649 ↗ “peginterferon alfa-2a (PEGASYS, PEG-IFNalfa-2a)” NCT00115908 ↗ “pegylated interferon (peg-IFN) alfa-2a” PMID 32556157 ↗ Nov 2021 “Peginterferon alfa-2a (pegIFN alfa-2a)” NCT01292239 ↗ “pegylated interferon (Peg-IFN) alfa-2a” NCT01054573 ↗ “Biological: pegIFN alfa-2a” NCT01332955 ↗ |
| Known as | peg-IFN alfa 2b | “peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW” NCT00842205 ↗ |
| Known as | Peg-IFN alfa-2a: Pegasys (Hoffman La-Roche) | “Peg-IFN alfa-2a: Pegasys (Hoffman La-Roche)” NCT00977054 ↗ |
| Known as | Peg-IFN-Alpha-2A | “comparing the efficacy and safety of telbivudine in combination with PegIFN alpha-2a with telbivudine monotherapy and PegIFN alpha-2a monotherapy.” PMID 25152207 ↗ Aug 20145“Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin” NCT01272310 ↗ “Pegylated Interferon-Alpha-2A (Peg-IFN-Alpha-2A:Pegasys®) on HIV-1 replication” NCT00594880 ↗ “peginterferon alfa (PEG-IFNalpha)-2a 180 microg one time per week (qwk)” PMID 18666223 ↗ Aug 2008 “Peginterferon alpha-2a (PegIFN alpha-2a)” NCT01281839 ↗ “Peginterferon alpha-2a (PegIFN alpha-2a)” NCT01289782 ↗ |
| Known as | Peg-IFN-α2a | “This randomized, prospective, parallel-group clinical trial compared the efficacy and safety of pegylated interferon α-2a (PEG-IFN α-2a) plus ribavirin and PEG-IFN α-2b plus...” PMID 21281434 ↗ Jan 201130“A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease...” NCT01500772 ↗ “AIM: To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and...” PMID 27062488 ↗ Jun 2016 “Telaprevir (TVR) plus peginterferon-α2a (PEG-IFN-α2a) and ribavirin substantially increases treatment efficacy for genotype 1 chronic hepatitis C virus (HCV) infection versus...” PMID 23685940 ↗ Jul 2013 “As there is currently a lack of consensus on the most appropriate dose and duration of peginterferon alfa-2a (PEG-IFNα-2a) therapy in hepatitis B e antigen (HBeAg)-positive patients” PMID 22045673 ↗ Nov 2011 “Children treated with pegylated interferon alpha-2a (Peg-IFN-α2a) ± ribavirin in the Pediatric Study of Hepatitis C (PEDS-C) trial underwent anthropometric measurements” PMID 22383118 ↗ Jul 2012 “Clinical Trial of the Efficacy of the Combination of Pegylated Interferon (PEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C” NCT00158496 ↗ “SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of \< 75 kg and 1200 mg/day for subjects with a BW of \> 75 kg)” NCT01335711 ↗ “Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.” NCT02216045 ↗ “PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.” NCT00882908 ↗ “Clinical Trial of the Efficacy of Pegylated Interferon (PEG-IFNα-2a) Alone in Egyptian Patients With Acute Hepatitis C” NCT00158522 ↗ “open-label Peg-IFN-α-2a (180 μg/week) and RBV (1,000-1,200 mg/day) in combination with blinded placebo or vaniprevir” PMID 22473713 ↗ Jul 2012 “Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week” NCT02021643 ↗ “The effect of pegylated interferon alpha-2a (PegIFN-α-2a) on virological relapse after NUC cessation is unknown.” PMID 39094743 ↗ Jul 2024 “Peg-IFNα-2a 180 μg every week, or albIFN 900 or 1200 μg every 2 weeks administered subcutaneously” PMID 20600013 ↗ Jun 2010 “PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day)” NCT01226771 ↗ “combined with pegylated interferon-α2a plus ribavirin (pegIFN-α2a/RBV) for 48 weeks” PMID 30858739 ↗ Feb 2019 “followed by PEG-IFNα-2a and ribavirin at standard doses and durations” PMID 23396509 ↗ Feb 2013 “weekly pegylated (Peg)-IFN-α2b or Peg-IFN-α2a immunotherapy” PMID 34049356 ↗ Oct 2021 “Drug: Pegylated interferon alfa-2a (PegIFNα-2a)” NCT01846832 ↗ “Pegylated Interferon Alfa-2a (pegIFNα-2a)” NCT01309932 ↗ “Drug: Peginterferon (PegIFNα-2a)” NCT00561353 ↗ |
| Known as | PEG-IFNa | “Treatment with PEG-IFNa with or without tenofovir disoproxil fumarate (TDF) for 96 weeks resulted in HDV RNA suppression” PMID 37787009 ↗ Oct 2023 |
| Known as | PEG-IFNa2a | “peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin” NCT00402428 ↗ |
| Known as | PEG-IFNα | “This observation was translated into a proof-of-concept phase 1/2 clinical trial with long-acting IFN-α (pegylated IFN-α [pegIFNα]) in patients undergoing HCT for high-risk...” PMID 34607341 ↗ Dec 202113“Until recently, pegylated interferon-alfa-2a (PEG-IFNα) therapy was the only treatment option for patients infected with hepatitis D virus (HDV).” PMID 41317314 ↗ Nov 2025 “Pegylated interferon α-2a(Peg-IFN-α) not only inhibit viral replication, but also play an important role in immune regulation” NCT03210506 ↗ |
| Known as | PEG-INF | “Peginterferon alpha-2a (PEG-INF) monotherapy: 180 μg subcutaneous injection once a week for 52 weeks.” NCT00412750 ↗ |
| Known as | Peg-interféron alpha-2a (PEGASYS) | “Peg-interféron alpha-2a (PEGASYS)” NCT01289496 ↗ |
| Known as | PEG-Intron(Trademark) | “PEG-Intron(Trademark) is a form of interferon alpha combined with monomethoxy polyethylene glycol (PEG).” NCT00036569 ↗ |
| Known as | Pegasys | “Pegylated interferon plus ribavirin is the standard first-line treatment in patients with chronic hepatitis C virus (HCV) mono-infection. Although the optimal anti-HCV regimen...” PMID 15563253 ↗ 2004120“A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group...” NCT00535847 ↗ “A Phase 2a, 2-Part, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study of Telaprevir in Combination With Peginterferon Alfa-2a (Pegasys®) and...” NCT00983853 ↗ “This study will evaluate the efficacy and safety of capecitabine (Xeloda) in combination with peginterferon alfa-2a (Pegasys) in participants with advanced liver cancer who...” NCT02576964 ↗ “An Open-label Trial of 48-week Peginterferon Alfa-2a (PEGASYS) to Assess the Sustained Response of Chronic Hepatitis B Patients With HBeAg Seroconversion on Nucleot(s)Ide...” NCT02068365 ↗ “Participants randomized to the control group immediately begin treatment with telaprevir + 180ug of peginterferon alfa-2a (Pegasys) per week and either weight based ribavirin.” NCT01890772 ↗ “SYREN Study: A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin) in Non-Responder Patients With Chronic Hepatitis C (CHC) Genotype 1.” NCT00412334 ↗ “Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.” NCT00107653 ↗ “Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day” NCT00495131 ↗ “Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day” NCT00532701 ↗ “Participants received peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once per week for 48 weeks.” NCT00436163 ↗ “For this study, 0.1 mcg Pegasys per injection site (x 4 injection sites) will be administered.” NCT06072612 ↗ “Eligible participants will be administered peginterferon alpha-2a [Pegasys] (40 kilo Dalton)” NCT00474955 ↗ “Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin” NCT00491244 ↗ “Active Treatment with Pegylated Interferon Alfa 2a (Pegasys, Roche) and ribavirin” NCT00203606 ↗ “Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks” NCT01519921 ↗ “peginterferon alfa-2a (PEGASYS or PEG-IFNa2a) in combination with ribavirin” NCT00402428 ↗ “Peginterferon alfa-2a (Pegasys, Hoffmann-LaRoche) 135 ug/week for 24 weeks” NCT00172809 ↗ “patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks” NCT01263860 ↗ “Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)” NCT02201459 ↗ “Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52” NCT00921180 ↗ “pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week” NCT01592006 ↗ “Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche)” NCT00491179 ↗ “Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®)” NCT00420784 ↗ “s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.” NCT01343186 ↗ “Pegasys (peginterferon alfa-2a) and Copegus (ribavirin)” NCT01447420 ↗ “Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week” NCT00470210 ↗ “with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk)” NCT00892697 ↗ “peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]” NCT00077649 ↗ “Pegylated interferon-alfa2a (Pegasys); ribavirin” NCT00152581 ↗ “Pegasys (peginterferon alfa-2a) pharmacokinetics” NCT01337375 ↗ “peginterferon alfa-2a (PEGASYS, PEG-IFNalfa-2a)” NCT00115908 ↗ “Pegylated Interferon Alfa-2a (Pegasys)” NCT01054573 ↗ “Drug: peginterferon alfa-2a [Pegasys]” NCT00922779 ↗ “Drug: peginterferon alfa-2a [Pegasys]” NCT00661076 ↗ “Drug: peginterferon alfa-2a [Pegasys]” NCT00614471 ↗ “Drug: peginterferon alfa-2a [Pegasys]” NCT00927082 ↗ “Drug: peginterferon alfa-2a [Pegasys]” NCT01483742 ↗ “Drug: peginterferon alfa-2a [Pegasys]” NCT01278134 ↗ “Drug: peginterferon alfa-2a [Pegasys]” NCT01179594 ↗ “PegIFN alfa-2a (PEgasys) 180 ug/week” NCT01056172 ↗ “pegylated interferon-alpha (Pegasys)” NCT00909129 ↗ “Peginterferon (Pegasys) (96 weeks)” NCT00917761 ↗ “PEG-Interferon-alpha 2a (Pegasys®)” NCT00088504 ↗ “Peginterferon alpha-2a (Pegasys®)” NCT00122616 ↗ “Peginterferon Alfa-2a (Pegasys®)” NCT00372385 ↗ “Peginterferon Alfa-2a (Pegasys®)” NCT00262483 ↗ “peginterferon alfa-2a [Pegasys]” NCT01057667 ↗ “peginterferon alfa-2a [Pegasys]” NCT00962871 ↗ “peginterferon alfa-2a [Pegasys]” NCT00087568 ↗ “Peginterferon Alfa-2a (Pegasys)” NCT01030432 ↗ “peginterferon alfa-2a [Pegasys]” NCT00962975 ↗ “peginterferon alfa-2a [Pegasys]” NCT00087594 ↗ “Peginterferon alfa-2a [Pegasys]” NCT00087607 ↗ “peginterferon alfa-2a [Pegasys]” NCT00087633 ↗ “peginterferon alfa-2a [Pegasys]” NCT00922207 ↗ “peginterferon alfa-2a [Pegasys]” NCT00087646 ↗ “Peginterferon alfa-2a [Pegasys]” NCT01787279 ↗ “peginterferon alfa-2a [Pegasys]” NCT00940420 ↗ “peginterferon alfa-2a [Pegasys]” NCT01585324 ↗ “peginterferon alfa-2a [Pegasys]” NCT01033448 ↗ “peginterferon alfa-2a [Pegasys]” NCT01903954 ↗ “peginterferon alfa-2a [Pegasys]” NCT01296971 ↗ “peginterferon alfa-2a (pegasys)” NCT01378104 ↗ “peginterferon alfa-2a [Pegasys]” NCT01591460 ↗ “peginterferon alfa-2a [Pegasys]” NCT01237496 ↗ “peginterferon alfa-2a [Pegasys]” NCT01088659 ↗ “peginterferon alfa-2a [Pegasys]” NCT00475072 ↗ “peginterferon alfa-2a [Pegasys]” NCT01749150 ↗ “peginterferon alfa-2a [Pegasys]” NCT01519960 ↗ “peginterferon alfa-2a [Pegasys]” NCT00487747 ↗ “peginterferon alfa-2a [Pegasys]” NCT01579019 ↗ “Peg-IFN alfa2a (Pegasys)” NCT00528528 ↗ “Pegasys” NCT01706575 ↗ |
| Known as | Pegasys (PEG-Interferon alpha-2a) | “Pegasys (PEG-Interferon alpha-2a)” NCT00207311 ↗ |
| Known as | Pegasys (PEG-interferon-Alfa-2A) | “Pegasys (PEG-interferon-Alfa-2A)” NCT01769833 ↗ |
| Known as | Pegasys(R) | “with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk)” NCT00892697 ↗ |
| Known as | Pegasys-Roche | “Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.” NCT02690103 ↗ |
| Known as | PegasysTM | “A Phase II Open-Label Pilot Trial of the Antiretroviral Activity, Safety, and Tolerability of Pegylated Interferon Alfa-2A (40KD) [PegasysTM] in HIV-1 Infected Subjects” NCT00078442 ↗ |
| Known as | pegIFNα-2a, Pegasys | “pegIFNα-2a, Pegasys®” NCT01428063 ↗1“PegIFNα-2a (Pegasys)” NCT01290679 ↗ |
| Known as | peginterferon | “We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial.” PMID 26453773 ↗ Oct 201526“maintenance dose of PEG interferon to delay progression of fibrosis and histologic damage, in non-responders to the initial regimen of PEG interferon and ribavirin.” NCT00167557 ↗ “To test 2 drugs (VIR-2218 and peginterferon) in people with mild or inactive HBV infection” NCT06092333 ↗ “Peginterferon 180 μg single dose S.C.” NCT02781753 ↗ “peginterferon/RBV” NCT00487318 ↗ |
| Known as | Peginterferon (PegIFNα-2a) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00561353 ↗ |
| Known as | Peginterferon alfa 2a 40kDA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01623336 ↗ |
| Known as | Peginterferon Alfa-2a (40KD) | “Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.” NCT00107653 ↗2“PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Ribavirin” NCT00475072 ↗ “Efficacy and Safety of Peginterferon Alfa-2a (40KD)” PMID 29689122 ↗ Oct 2018 |
| Known as | Peginterferon alfa-2a (PegIFNα-2a ) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01288209 ↗ |
| Known as | Peginterferon alpha-2a | “The researchers aim to investigate the ability of peginterferon alpha-2a to achieve surface antigen loss/seroconversion therapy in inactive carriers with persistently normal...” NCT01471535 ↗31“GOALS: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a...” PMID 23442834 ↗ Oct 2013 “This study will evaluate the safety and effectiveness of combination therapy with peginterferon alpha-2a and ribavirin for treating hepatitis C virus (HCV) infection in...” NCT00085917 ↗ “Two hundred HCV-1 patients were randomized (1:1) to either 24 or 48 weeks of peginterferon-alpha-2a (180 microg/week) and ribavirin (1000-1200 mg/day) with a 24-week follow-up.” PMID 18508296 ↗ Jun 2008 “Pilot Study on Efficacy and Tolerance of Peg-interferon Alpha-2a (Pegasys) Added to Tenofovir DF and Emtricitabine (Truvada) in AGHBe Positive HBV-HIV Co-infected Patients.” NCT00391638 ↗ “Peginterferon alpha-2a (40KD) is a modified form of interferon alpha-2a consisting of a branched polyethylene glycol (PEG) chain covalently bound to interferon alpha-2a.” NCT00172809 ↗ “Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin” NCT00028093 ↗ “Subjects will receive low dose peginterferon alpha-2a on the same day as cell inoculation.” NCT06471673 ↗ “Induction Doses of Peginterferon Alpha-2a (40 KD) (270 μg/Week)” NCT00356486 ↗ |
| Known as | Peginterferon alpha-2a (40 kD) PEGASYS | “Peginterferon alpha-2a (40 kD) PEGASYS” NCT01380938 ↗ |
| Known as | peginterferon-alfa | “with and without peginterferon-alfa, in treatment-experienced patients with cirrhosis and” PMID 26248087 ↗ Aug 2015 |
| Known as | peginterferonα2a | “We evaluated HBsAg loss in patients receiving the combination of tenofovir disoproxil fumarate (TDF) and peginterferon α-2a (peginterferon) for a finite duration in a randomized trial.” PMID 26453773 ↗ Oct 20151“Treatment naïve patients with CHC, GT 2/3 were randomized to receive 180 μg peginterferonα2a/week in combination with either 800 (group C) or 400 mg/d (group D) for 16 weeks.” PMID 21714878 ↗ Jun 2011 |
| Known as | Peglated Interferon Alfa-2B | “A Phase II Study of Temozolomide (Temodar) and Peglated Interferon Alfa-2B (PEGIntron) in the Treatment of Advanced Melanoma” NCT00027742 ↗ |
| Known as | Pegnano (Peginterferon alfa-2a) | “Pegnano (Peginterferon alfa-2a)” NCT06922643 ↗ |
| Known as | PEGrIFN-α | “Pegylated interferon (PEGrIFN-α, Pegasys)” NCT00962715 ↗ |
| Known as | pegylated IFN-α | “This observation was translated into a proof-of-concept phase 1/2 clinical trial with long-acting IFN-α (pegylated IFN-α [pegIFNα]) in patients undergoing HCT for high-risk...” PMID 34607341 ↗ Dec 2021 |
| Known as | Pegylated Interferon | “This Phase II study is being conducted in treatment-naive patients (no previous antiviral therapy for Hepatitis C infection) with genotype-1 chronic hepatitis C to evaluate the...” NCT00118768 ↗41“Less than half of patients infected with hepatitis C virus (HCV) achieve sustained viral clearance after pegylated interferon (peginterferon) and ribavirin therapy.” PMID 20854821 ↗ Sep 2010 “The sustained-release form of the drug, pegylated interferon, is given just once a week.” NCT00023322 ↗ “pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly” NCT01826981 ↗ “Weekly pegylated interferon injections will be administered by clinic staff” NCT00399672 ↗ “Pegylated Interferon (PegIFN) and ribavirin (RBV)” NCT01330316 ↗ “pegylated interferon (Peg-IFN)” NCT01625338 ↗ |
| Known as | pegylated interferon (Peg-IFN) alfa-2a | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01054573 ↗ |
| Known as | Pegylated interferon (PegIFN) | “Pegylated interferon (PegIFN)” NCT03357822 ↗ |
| Known as | Pegylated Interferon (Peginterferon) Alfa-2a | “Pegylated Interferon (Peginterferon) Alfa-2a” NCT01706575 ↗ |
| Known as | pegylated interferon alfa | “Here we provide a randomized evaluation of the small interfering RNA elebsiran, in combination with pegylated interferon alfa (PEG-IFNα), compared with PEG-IFNα monotherapy.” PMID 41203919 ↗ Nov 20258“Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01565889 ↗ “pegylated interferon alfa (Peg IFN)(180ug subcutaneous once weekly)” NCT01582035 ↗ |
| Known as | Pegylated Interferon alfa-2a | “A Phase II Randomized, Multicenter, Open-label Study of TG4040 (MVA-HCV) in Combination With Pegylated Interferon Alfa-2a and Ribavirin Versus Pegylated Interferon Alfa-2a and...” NCT01055821 ↗81“The aim of this study was to compare the pharmacokinetic properties of BIP48 (pegylated interferon alfa-2b from Bio-Manguinhos/Fiocruz, Brazil) to those of PEGASYS®...” PMID 29301580 ↗ Jan 2018 “An Open-Label Safety and Tolerability Study of Nitazoxanide, Pegylated-Interferon Alfa 2a and Ribavirin in HIV/HCV Co-Infected Genotype 1 Prior Treatment Relapsers and Non-Responders” NCT01185028 ↗ “pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment” NCT00085917 ↗ “Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B is associated with an unexpected high rate of peripheral neuropathy.” PMID 25152207 ↗ Aug 2014 “Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.” NCT00132210 ↗ “A Phase II Study of Adefovir Dipivoxil, Pegylated Interferon Alfa-2A, and Ribavirin Treatment in HBV and HCV Infected Subjects With HIV Disease” NCT00051077 ↗ “Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.” PMID 18650451 ↗ Jul 2008 “Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally” NCT00932971 ↗ “Pegylated interferon alfa-2a (Peg-IFNα-2a) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week” NCT02021643 ↗ “Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks” NCT00629967 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.” NCT01054729 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.” NCT01188772 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection” NCT02480686 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01384383 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01497366 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01329978 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT02583685 ↗ “Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection” NCT01641640 ↗ “Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication” PMID 23105144 ↗ Oct 2012 “Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin” NCT00491244 ↗ “Pegasys (pegylated interferon alfa-2a) plus placebo versus Pegasys plus tenofovir” NCT01088659 ↗ “pegylated interferon alfa-2a (PEG-IFN)” NCT00078403 ↗ “pegylated-interferon alfa-2a (PEG-IFN)” NCT00003542 ↗ “Pegasys (pegylated interferon alfa-2a)” NCT00275548 ↗ “Pegylated Interferon Alfa-2a” NCT01259817 ↗ |
| Known as | pegylated interferon Alfa-2a (40KD) | “A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.” PMID 25190434 ↗ Sep 2014 |
| Known as | Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) | “Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche)” NCT00491244 ↗ |
| Known as | Pegylated interferon alfa-2a (Pegasys, Hoffman-La Roche) | “Pegylated interferon alfa-2a (Pegasys, Hoffman-La Roche)” NCT00917358 ↗ |
| Known as | Pegylated interferon alfa-2a (pegIFNα-2a) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01616524 ↗ |
| Known as | Pegylated interferon alfa-2a (Reiferon Retard 160 µg ) | “Pegylated interferon alfa-2a (Reiferon Retard 160 µg ®)” NCT01896609 ↗ |
| Known as | pegylated interferon-alpha | “A Phase III, Randomised, Double-blind and Placebo-controlled Study of Once Daily BI 201335 120 mg for 12 or 24 Weeks or BI 201335 240 mg for 12 Weeks in Combination With...” NCT01343888 ↗1“pegylated interferon-alpha (Pegasys)” NCT00909129 ↗ |
| Known as | pegylated interferon-α2a | “A Multicenter, Single-arm Trial Evaluating the Safety and Efficacy of DEB025/Alisporivir in Combination With Pegylated Interferon-α2a and Ribavirin (Peg-IFNα2a/RBV) in Protease...” NCT01500772 ↗4“AIM: To assess the efficacy and safety of telaprevir (TVR) in combination with pegylated interferon α-2a (PEG-IFNα-2a) and ribavirin (RBV) for treatment-naïve patients and...” PMID 27062488 ↗ Jun 2016 “Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.” PMID 25710287 ↗ Mar 2015 “ASC42 Tablets in Combination With Entecavir and Pegylated Interferon α-2a in Subjects With Chronic Hepatitis B Virus” NCT05107778 ↗ “pegylated interferon-α2a, 135 µg weekly, plus” PMID 24297189 ↗ Dec 2013 |
| Known as | pegylated-IFN | “Drug: pegylated-IFN” NCT01664845 ↗ |
| Known as | pegylated-interferon a2b | “weekly sc pegylated-interferon a2b (Peg-INF)(1.5 mcg/kg/week)” NCT00979706 ↗ |
| Known as | pegylated-interferon alpha-2a | “This protocol is an open label, single arm, non-randomized, phase I / II clinical trial investigating the use of pegylated interferon alpha-2a (peg-IFN-α, Pegasys®, Genentech)...” NCT02328755 ↗37“After medical evaluation and pretreatment liver biopsy, treatment with subcutaneous injections of pegylated interferon alpha-2a 180 g per week will be given for a total of 24...” NCT02364336 ↗ “pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1...” NCT00629824 ↗ “Coinfected and monoinfected patients were enrolled in a treatment trial for pegylated-interferon alpha-2a (peg-IFN) + ribavirin.” PMID 17058240 ↗ Nov 2006 “pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks” NCT00629967 ↗ “Vaniprevir with pegylated interferon alpha-2a and ribavirin in treatment-naïve” PMID 22473713 ↗ Jul 2012 “Pegylated interferon-alpha 2a 180 micrograms s.c. weekly” NCT00909129 ↗ “nilotinib + pegylated interferon alpha 2a (PEG-IFN).” NCT01294618 ↗ |
| Known as | pIFN | “pIFN (peginterferon alfa-2a)” NCT07288112 ↗ |
| Known as | Reiferon R | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02027493 ↗ |
| Known as | Reiferon retard | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01649245 ↗ |
| Known as | RO 25-8310 | “A Phase IIIb Parallel Group, Open Label Study of Pegylated Interferon Alfa-2a Monotherapy (PEG-IFN, Ro 25-8310) Compared to Untreated Control” NCT01519960 ↗2“A Phase III Study of Ro25-8310 (Peginterferon Alfa-2a) in Combination With Ro20-9963 (Ribavirin) in Patients With Chronic Hepatitis C” NCT00144469 ↗ “Pegylated-Interferon Alpha-2A (RO 25-8310)” NCT00003542 ↗ |
| Action | Inhibit | “will suppress Hepatitis C virus” NCT00006164 ↗ |
| Modality | Protein / enzyme biologic | “Peginterferon alfa-2a (pegylated interferon)” NCT00006164 ↗ |
| Route | Other | “90 mcg/week injection” NCT00006164 ↗ |